Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc., 55689 [2020-19868]

Download as PDF 55689 Federal Register / Vol. 85, No. 175 / Wednesday, September 9, 2020 / Notices BPI in the preliminary phase of the investigation need not reapply for such access. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO. Staff report.—The prehearing staff report in the final phase of this investigation will be placed in the nonpublic record on December 22, 2020, and a public version will be issued thereafter, pursuant to § 207.22 of the Commission’s rules. Hearing.—The Commission will hold a hearing in connection with the final phase of this investigation beginning at 9:30 a.m. on Tuesday, January 12, 2021. Information about the place and form of the hearing, including about how to participate in and/or view the hearing, will be posted on the Commission’s website at https://www.usitc.gov/ calendarpad/calendar.html. Interested parties should check the Commission’s website periodically for updates. Requests to appear at the hearing should be filed in writing with the Secretary to the Commission on or before January 7, 2021. A nonparty who has testimony that may aid the Commission’s deliberations may request permission to present a short statement at the hearing. All parties and nonparties desiring to appear at the hearing and make oral presentations should participate in a prehearing conference to be held on January 8, 2021, if deemed necessary. Oral testimony and written materials to be submitted at the public hearing are governed by §§ 201.6(b)(2), 201.13(f), and 207.24 of the Commission’s rules. Parties must submit any request to present a portion of their hearing testimony in camera no later than 7 business days prior to the date of the hearing. Written submissions.—Each party who is an interested party shall submit a prehearing brief to the Commission. Prehearing briefs must conform with the provisions of § 207.23 of the Commission’s rules; the deadline for filing is January 5, 2021. Parties may also file written testimony in connection with their presentation at the hearing, as provided in § 207.24 of the Commission’s rules, and posthearing briefs, which must conform with the provisions of section 207.25 of the Commission’s rules. The deadline for filing posthearing briefs is January 20, 2021. In addition, any person who has not entered an appearance as a party to the investigation may submit a written statement of information pertinent to the subject of the investigation, including statements of support or opposition to the petition, on or before VerDate Sep<11>2014 17:06 Sep 08, 2020 Jkt 250001 January 20, 2021. On February 3, 2021, the Commission will make available to parties all information on which they have not had an opportunity to comment. Parties may submit final comments on this information on or before February 5, 2021, but such final comments must not contain new factual information and must otherwise comply with § 207.30 of the Commission’s rules. All written submissions must conform with the provisions of § 201.8 of the Commission’s rules; any submissions that contain BPI must also conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s Handbook on Filing Procedures, available on the Commission’s website at https:// www.usitc.gov/documents/handbook_ on_filing_procedures.pdf, elaborates upon the Commission’s procedures with respect to filings. Additional written submissions to the Commission, including requests pursuant to § 201.12 of the Commission’s rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff. In accordance with §§ 201.16(c) and 207.3 of the Commission’s rules, each document filed by a party to the investigation must be served on all other parties to the investigation (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service. Authority: This investigation is being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.21 of the Commission’s rules. By order of the Commission. Issued: September 2, 2020. Lisa Barton, Secretary to the Commission. Drug Enforcement Administration [Docket No. DEA–704] Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc. Frm 00054 Fmt 4703 Sfmt 4703 Controlled substance Oxymorphone ................ Fentanyl ......................... Drug code 9652 9801 Schedule II II The company is a contract manufacturer. At the request of the company’s customers, it manufactures derivatives of controlled substances in bulk form. William T. McDermott, Assistant Administrator. [FR Doc. 2020–19868 Filed 9–8–20; 8:45 am] BILLING CODE P [OMB Number 1117–0043] Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement of a Previously Approved Collection: Drug Questionnaire (DEA–341) DEPARTMENT OF JUSTICE PO 00000 In accordance with 21 CFR 1301.33(a), this is notice that on August 6, 2020, Nanosyn Inc., 3331 Industrial Drive, Suite B, Santa Rosa, California 95403– 2062, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substances: SUPPLEMENTARY INFORMATION: Drug Enforcement Administration BILLING CODE 7020–02–P Drug Enforcement Administration, Justice. ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before November 9, 2020. Such persons may also file a written request for a hearing on the application on or before November 9, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: DEPARTMENT OF JUSTICE [FR Doc. 2020–19831 Filed 9–8–20; 8:45 am] AGENCY: Nanosyn Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substances. Refer to Supplemental Information listed below for further drug information. SUMMARY: Drug Enforcement Administration, Department of Justice. ACTION: 60-Day notice. AGENCY: The Drug Enforcement Administration, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in SUMMARY: E:\FR\FM\09SEN1.SGM 09SEN1

Agencies

[Federal Register Volume 85, Number 175 (Wednesday, September 9, 2020)]
[Notices]
[Page 55689]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19868]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-704]


Bulk Manufacturer of Controlled Substances Application: Nanosyn 
Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Nanosyn Inc. has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substances. Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before November 9, 
2020. Such persons may also file a written request for a hearing on the 
application on or before November 9, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on August 6, 2020, Nanosyn Inc., 3331 Industrial Drive, 
Suite B, Santa Rosa, California 95403-2062, applied to be registered as 
an bulk manufacturer of the following basic class(es) of controlled 
substances:

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Oxymorphone............................     9652  II
Fentanyl...............................     9801  II
------------------------------------------------------------------------

    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of controlled 
substances in bulk form.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-19868 Filed 9-8-20; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.